"Applicability and Cost Implications for Proprotein Convertase Subtilis" by Khurram Nasir

Menu

Skip to main content

All Publications

Khurram Nasir, Baptist Health Medical GroupFollow

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Publication Date

2019

Content Type

Article

PubMed ID:

Additional Authors:

Additional authors and institutional affiliations

Citation

Circulation (2019) 139(3):410-412

Restricted

Available to BHSF community via local IP address or BHSF login.

Find in your library

COinS